<DOC>
	<DOCNO>NCT00423852</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , ifosfamide , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . An autologous peripheral stem cell transplant may able replace blood-forming cell destroy chemotherapy . This may allow chemotherapy give tumor cell kill . PURPOSE : This phase I/II trial study side effect best dose ifosfamide give together paclitaxel carboplatin follow autologous stem cell transplant see well work treat patient germ cell tumor respond cisplatin .</brief_summary>
	<brief_title>Paclitaxel , Ifosfamide , Carboplatin Followed By Autologous Stem Cell Transplant Treating Patients With Germ Cell Tumors That Did Not Respond Cisplatin</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety paclitaxel ifosfamide follow dose-escalated , dose-intensive paclitaxel , carboplatin , ifosfamide autologous peripheral blood stem cell support patient cisplatin-resistant germ cell tumor . ( Phase I ) - Determine maximum tolerate dose paclitaxel , carboplatin , ifosfamide give high-dose treatment program patient . ( Phase I ) - Determine efficacy regimen give salvage therapy second-line third-line setting , term complete response , patient . ( Phase II ) OUTLINE : This phase I , dose-escalation study paclitaxel , carboplatin , ifosfamide follow phase II , open-label study . - Phase I : - Paclitaxel , ifosfamide , autologous peripheral blood stem cell ( PBSC ) collection : Patients receive paclitaxel IV 3 hour day 1 ifosfamide IV 2 hour day 1-3 . Patients undergo leukapheresis day 11-13 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) twice daily begin day 3 continue leukapheresis complete . Beginning day 14 21 , patient may receive second course paclitaxel , ifosfamide , G-CSF . Patients may also undergo additional leukapheresis . - Paclitaxel , carboplatin , ifosfamide , autologous PBSC transplantation : Patients receive paclitaxel IV 3 hour , high-dose carboplatin IV 30 minute , ifosfamide IV 4 hour day 1-3 . Patients also receive G-CSF SC begin day 3 continue blood count recover . Patients undergo reinfusion autologous PBSCs day 5 . Treatment repeat every 21-28 day 3 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos paclitaxel , carboplatin , ifosfamide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive treatment phase I paclitaxel , carboplatin , ifosfamide MTD determine phase I . After completion study treatment , patient follow periodically 1 year annually thereafter .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Teratoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm germ cell tumor ( GCT ) Primary CNS GCT allow Unidimensionally measurable disease OR elevate serum tumor marker ( alphafetoprotein and/or human chorionic gonadotropin ) Advanced disease Disease resistant cisplatinbased chemotherapy regimen ( i.e. , fail achieve durable complete response cisplatin ) Known residual disease postchemotherapy surgery allow PATIENT CHARACTERISTICS : Platelet count ≥ 100,000/mm^3 WBC ≥ 3,000/mm^3 Creatinine clearance &gt; 50 mL/min ( unless due tumor obstruct ureter ) AST ALT &lt; 2 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection Negative serology HIV type I II , human Tlymphotropic virus type I II , hepatitis B C virus , syphilis , cytomegalovirus Hepatitis C negative serology RIBA PCR Adequate medical condition general anesthesia PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered recent surgery At least 3 week since prior chemotherapy No prior highdose therapy autologous bone marrow transplantation No concurrent chemotherapy No concurrent treatment ( e.g. , surgery radiotherapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>stage II malignant testicular germ cell tumor</keyword>
	<keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>recurrent extragonadal seminoma</keyword>
	<keyword>stage III extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage III extragonadal seminoma</keyword>
	<keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage IV extragonadal seminoma</keyword>
	<keyword>recurrent extragonadal germ cell tumor</keyword>
	<keyword>adult teratoma</keyword>
	<keyword>testicular immature teratoma</keyword>
	<keyword>testicular mature teratoma</keyword>
</DOC>